TP03HN106 in Patients With Critical Limb Ischemia

Launched by TALENGEN INSTITUTE OF LIFE SCIENCES, SHENZHEN, P.R. CHINA. · Jun 25, 2024

Keywords

ClinConnect Summary

This clinical trial, named TP03HN106, is studying a potential new treatment for patients suffering from Critical Limb Ischemia (CLI), a serious condition where blood flow to the legs is severely reduced. CLI can cause pain while resting, ulcers, and in some cases, may lead to amputation. The purpose of this study is to see if the investigational drug TP03HN106 can help dissolve blood clots and improve blood flow, potentially alleviating the symptoms of CLI.

To be eligible for the trial, participants must be at least 18 years old and have been diagnosed with CLI, specifically with a certain level of severity (a Rutherford score of 4-6). Those who can't have surgery or whose previous treatments haven't worked might be good candidates. Participants will receive the new treatment while being monitored closely. It's important to know that anyone with severe allergic reactions to the drug, certain serious health conditions, or who is pregnant or breastfeeding cannot participate. If you or a loved one is experiencing symptoms of CLI and would like to learn more about this trial, please consider discussing it with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. When signing the informed consent form, the age should be ≥ 18 years old, regardless of gender;
• • 2. Clinically diagnosed as a patient with Critical limb ischemia, with a Rutherford score of 4-6.
• • 3. Patients who are unable to undergo interventional surgical treatment, or whose previous interventional surgical treatment is ineffective, or who are unwilling to undergo any intervention or surgical treatment, and can only receive conventional antiplatelet and vasodilator drugs (before baseline, antiplatelet and vasodilator drugs must be used for at least 1 week);
• • 4. During the screening period, lower limb artery color ultrasound or lower limb computed tomography angiography (CTA) showed severe stenosis or occlusion of one or more of the common iliac artery, external iliac artery, common femoral artery, superficial femoral artery, popliteal artery, anterior tibial artery, posterior tibial artery, and fibular artery;
• • 5. During the screening period, if there are severe symptoms of lower limb ischemia, meeting any of the following symptoms is sufficient: There is limb rest pain caused by lower limb ischemia, with a disease duration of ≥ 2 weeks, and a VAS score of ≥ 40mm and \< 100mm before the first administration; There are limb tissue ulcers caused by lower limb ischemia, with a disease duration of ≥ 2 weeks and limb ulcers (4cm2 ≤ maximum single ulcer area ≤ 25cm2);
• • 6. All subjects with fertility or their spouses must take effective contraceptive measures within 3 months after signing the informed consent form until the completion of the trial;
• • 7. The subjects voluntarily give informed consent and sign an informed consent form (if the subjects and/or their guardians lack reading ability and cannot understand the content of the informed consent, they need to sign together with a fair witness), fully understand the methods and procedures of the experiment, and be able to provide biological samples for testing related indicators in accordance with the experiment requirements.
• Exclusion Criteria:
• • 1. Subjects who are known to be allergic to the investigational drug, its excipients, or other human blood products;
• • 2. Patients with limb gangrene greater than 4 cm2;
• • 3. Patients currently suffering from malignant tumor diseases (including those who have previously had malignant tumors but have not been cured);
• 4. Screening period for patients with liver and kidney failure:
• • 5. Patients who require hemodialysis;
• • 6. Those who have experienced cerebral infarction or cerebral hemorrhage within 3 months prior to signing the informed consent form;
• • 7. During the screening period, subjects with mental illness, obvious mental disorders or epilepsy, including other individuals with no behavioral or cognitive abilities;
• • 8. Hypertensive patients (SBP ≥ 160mmHg and/or DBP ≥ 100mmHg) who cannot be controlled after standardized treatment in the screening period;
• • 9. Individuals who have received fresh plasma, cold precipitates, or blood products containing TP03HN106 components within one month prior to signing the informed consent form;
• • 10. Those who have participated in clinical trials of other drugs or medical devices within one month before signing the informed consent form;
• • 11. Those who have undergone or plan to undergo surgery during the trial period within one month prior to signing the informed consent form;
• • 12. Alcoholism and/or psychoactive substances, drug abusers and dependents (alcoholism standard: the weekly alcohol intake is more than 21 units (male) and 14 units (female) (1 unit=360 mL beer; or 150 mL wine; or 45 mL white spirit);
• • 13. Miscarriage or termination of pregnancy less than 3 months prior to signing the informed consent form, pregnant women and lactating women (currently breastfeeding or not artificially breastfeeding but less than 6 months after delivery);
• • 14. Poor compliance or any other situation that the researcher deems unsuitable for inclusion.